Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. (Nasdaq: PGEN) is a pioneering biopharmaceutical company dedicated to discovering and developing next-generation gene and cellular therapies in the United States. Specializing in disease-modifying therapeutics, Precigen has been at the forefront of genetic engineering and synthetic biology solutions. The company excels in creating innovative therapies for some of the most challenging diseases in areas such as immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen's core technologies include:
- UltraVector® Platform: This platform incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs.
- UltraCAR-T® Cell Therapies: These therapies address limitations of conventional CAR-T therapies by improving in vivo CAR-T expansion and persistence, adding safety features, and reducing manufacturing costs.
- AdenoVerse™ Technology Platform: A library of engineered adenovector serotypes, including gorilla adenovectors, which is used for gene delivery, and modulating immune responses.
- RheoSwitch® Inducible Gene Switch: This technology allows for precise control over gene expression, making therapies safer and more efficient.
Recent achievements include the Phase 2 pivotal study data for PRGN-2012 in treating recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. The study showcased promising results, with 51% of patients achieving Complete Response, defined as no need for surgical interventions in the 12-month period following treatment.
Precigen is also actively developing UltraCAR-T therapies, which have demonstrated significant preliminary efficacy and safety advantages over existing CAR-T therapies. These therapies are currently being evaluated in clinical trials for various hematological and solid tumors.
Financially, Precigen has shown resilience, focusing on sound fiscal management while advancing its clinical pipeline. Despite experiencing fluctuations in research expenses and revenues, the company remains committed to achieving its milestones and maintaining a strong balance sheet.
Precigen's business model involves commercializing its technologies through collaborations with industry partners who possess specialized expertise, development resources, and sales capabilities. This collaborative approach enables Precigen to bring new and improved products to market efficiently.
For the latest updates on Precigen's innovative gene and cell therapies, visit their official website and follow them on social media platforms like X (formerly Twitter), LinkedIn, and YouTube.
On April 26, 2023, Precigen (Nasdaq: PGEN) announced its participation in the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago, Illinois. The company will present clinical data on two innovative therapies: PRGN-3005 UltraCAR-T for advanced, recurrent platinum-resistant ovarian cancer and PRGN-2009 AdenoVerse immunotherapy for HPV-associated cancers. Highlights include:
- PRGN-3005: Phase 1/1b study demonstrating the potential of overnight manufactured UltraCAR-T cells.
- PRGN-2009: Phase 1 study evaluating its effectiveness alone and with an anti-PDL1/TGF-Beta trap checkpoint inhibitor.
Event details and updates can be found on Precigen's investor website.
Precigen, Inc. (Nasdaq: PGEN) presented preclinical data for its next-generation UltraCAR-T platform using a mesothelin (MSLN) CAR at the AACR Annual Meeting 2023. MSLN is overexpressed in various solid tumors including mesothelioma and pancreatic cancer.
The new UltraCAR-T cells feature a novel mechanism for intrinsic PD-1 blockade, aiming to enhance safety and efficacy by eliminating the need for expensive checkpoint inhibitors. Results showed robust UltraCAR-T cell expansion and durable persistence leading to significant antitumor effects in preclinical models, even after tumor rechallenges. Collectively, these findings position the UltraCAR-T platform as a promising candidate in the cancer treatment landscape.
Precigen (NASDAQ: PGEN) has amended its license agreement with Alaunos Therapeutics, regaining exclusive rights to IL-12 gene therapy and proven CAR-T targets CD19 and BCMA. This amendment eliminates future royalties to Alaunos and enhances Precigen's ability to develop and commercialize UltraCAR-T therapies. The UltraCAR-T platform aims to deliver personalized treatments with overnight manufacturing, potentially transforming cancer therapy. The company is progressing its clinical programs for various cancers while planning a business and clinical update call on April 4, 2023.
Precigen, Inc. (NASDAQ: PGEN) announced the first patient dosing in the Phase 1/1b study of PRGN-3007, an investigational UltraCAR-T therapy targeting advanced ROR1-positive hematological and solid tumors. This innovative therapy integrates PD-1 checkpoint inhibition and aims to simplify and reduce costs associated with current treatments by eliminating the need for systemic checkpoint inhibitors. The clinical trial will enroll patients with chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and diffuse large B-cell lymphoma. With over 100,000 patients diagnosed in the U.S., E.U., and Japan in 2023, this development marks a significant milestone for Precigen's advanced cancer therapies.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What does Precigen, Inc. specialize in?
What are some of Precigen's core technologies?
What are the key areas of focus for Precigen's therapies?
What recent achievements has Precigen made?
How does Precigen commercialize its technologies?
What makes UltraCAR-T® Cell Therapies unique?
What is the AdenoVerse™ Technology Platform?
Where can I find more information about Precigen's latest updates?
What financial strategies does Precigen employ?
What is the RheoSwitch® Inducible Gene Switch?
